Allarity Therapeutics Expands Phase 2 Stenoparib Trial to Three Ovarian Cancer Patient Cohorts
Globe Newswire•16/11/2026•07:50 ET
0
Key Highlights
- ➤Allarity expands Phase 2 stenoparib trial to three ovarian cancer cohorts
- ➤New cohorts add primary platinum-refractory and clinically evaluable, non-RECIST disease
- ➤Earlier data showed median overall survival of 22 months with stenoparib
- ➤One patient with primary platinum-refractory disease received treatment nearly one year
- ➤Some platinum-resistant patients remained on stenoparib nearly 2.5 years
Expert Statements
Kathleen N. Moore, M.D., M.S., Principal Investigator of the Phase 2 stenoparib trial; Deputy Director and Director of Phase I Oncology Trials at the Fred & Pamela Buffett Cancer Center; Professor in the Department of Obstetrics and Gynecology at the University of Nebraska Medical Center
“We are excited about the expansion of eligibility to include patients with primary platinum-refractory disease as well as those with resistant but not measurable disease, allowing access to a potentially effective therapeutic agent among patients routinely excluded from clinical trial participation. We are hopeful that these patients will benefit from stenoparib and that we can learn more about best treatment options for all patients with ovarian cancer.”
Thomas Jensen, Chief Executive Officer of Allarity Therapeutics
“We're encouraged by the progress we’ve seen in the trial, and we’re excited to build on it”
Thomas Jensen, Chief Executive Officer of Allarity Therapeutics
“The strategic expansion of patient eligibility in this trial allows us to efficiently map the potential of stenoparib across multiple high-unmet-need populations. A strong result in any one of the three groups could support further development. And if the data support development in more than one group, stenoparib could ultimately reach more patients and address a larger market.”
Investigator-supported move capitalizes on strong enrollment momentum and encouraging early clinical observations
Adds platinum-refractory patients as well as those with hard-to-measure but clinically evaluable disease
Get started
Create a free account to read the full story.
